Company: INKT
Filing Date: 2025-12-10
Form Type: S-3/A
Source: 0001193125-25-314252
Chunk: 6

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-12-10
Form: S-3/A
Chunk 6
---
 Industry Data

Unless
otherwise indicated, information contained in this prospectus and any accompanying prospectus supplement concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is
based on our management’s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. We believe that

1

the information from these third-party publications, research, surveys and studies included in this prospectus and any accompanying prospectus supplement is reliable. Management’s estimates
are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of assumptions and limitations which are
necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in “Risk Factors.” These and other factors could cause our future performance to differ materially from our assumptions
and estimates.

References in this prospectus to the terms “the Company,” “MiNK,” “we,”
“our” and “us” or other similar terms mean MiNK Therapeutics, Inc. and its subsidiaries, unless we state otherwise or the context indicates otherwise.

2

SUMMARY

This summary highlights selected information contained elsewhere or incorporated by reference in this prospectus. The summary may not contain
all the information that you should consider before investing in our securities. You should read the entire prospectus carefully, including “Risk Factors” contained in this prospectus and the documents incorporated by reference herein,
before making an investment decision.

Company Overview

We are a clinical-stage biopharmaceutical company developing
first-in-class, off-the-shelf invariant natural killer T (iNKT) cell therapies designed
to treat cancer and immune-mediated diseases. Our therapies are based on a proprietary platform of allogeneic, ex-vivo expanded iNKT cells—cells that are designed to uniquely combine the precision and
memory of adaptive T cells with the speed and potency of natural killer (NK) cells. This rare biology is designed to allow iNKT cells to navigate tissues, eliminate tumors and infected cells, and reprogram the immune environment—all without
graft-versus-host disease (GVHD).

We believe iNKT cells represent an optimal platform for off-the-shelf cellular immunotherapy. Unlike conventional T or NK cell therapies, our iNKT cells can persist without lymphodepletion and function without the need for human leukocyte antigen (HLA) matching.
This allows